FDA orphan status for VAL001

Respitorius, a leading pharmaceutical firm has announced that US Food and Drug Administration has granted orphan drug status for VAL001 (valproic acid) .

Release Date: 14-Apr-2017



Respitorius, a leading pharmaceutical firm has announced that US Food and Drug Administration has granted orphan drug status for VAL001 (valproic acid) for the treatment of diffuse large b-cell lymphoma. The drug is presently undergoing 1/2a clinical phase trial.
Orphan Drug Designation is granted to drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon marketing approval for the designated indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and the waiver of prescription drug user fees.
“Global Orphan Drug Clinical Pipeline Insight” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.
 
 
 
For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com          

Need custom market research solution? We can help you with that too.